Bayer HealthCare Pharmaceuticals Inc. and Intendis Inc. will co-promote YAZ® (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control.
The said agreement took effect May 1, 2007 as part of an overall strategy to introduce dermatologists to the anti-acne benefits of YAZ®.
USFDA-approved in January 2007 as a treatment for moderate acne in women who desire an oral contraceptive for birth control, YAZ® is the only oral contraceptive approved for the treatment of premenstrual dysphoric disorder (PMDD) in women who desire an oral contraceptive for birth control.
[PMDD is a condition in which women's premenstrual symptoms are severe enough to impact activities, work or relationships.]
According to Stefan Oelrich, Vice President of Women's Healthcare, Bayer Healthcare Pharmaceuticals:
"Ob/gyns and now, dermatologists and their patients, are looking for contraceptive methods that go beyond birth control. YAZ is an ideal example of a treatment offering multiple benefits to more effectively meet women's needs.
This alliance combines the strengths of two Bayer businesses --- Bayer HealthCare Pharmaceutical's leadership in women's health and Intendis' established dermatology franchise – to support an important milestone in the lifecycle of YAZ."
Bayer HealthCare Pharmaceuticals Inc. is a U.S.-based pharmaceuticals unit of Bayer HealthCare while Intendis Inc. is a U.S.-based affiliate of Bayer Schering Pharma AG, Germany.
Read the full report.
Comment Preview